Purpose To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients
with advanced non—small-cell lung cancer (NSCLC) previously treated with chemotherapy …

Background The combination of pemetrexed and carboplatin is commonly used for the
treatment of advanced non-squamous non-small cell lung cancer (NSCLC), mainly because …

Background This phase III randomized trial compared pemetrexed 500 mg/m 2 (P500) with
pemetrexed 900 mg/m 2 (P900) to determine whether higher dosing benefits non-small-cell …

To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum
regimens in patients with previously untreated advanced non-small cell lung cancer …

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy
reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI …

Background The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …

Background: Preclinical data indicated that the combination of erlotinib and pemetrexed is
synergistic when erlotinib is administered after pemetrexed. Patients and Methods: This was …

Until recently, the treatment of non–small cell lung cancer (NSCLC) was limited to the
cisplatin combinations, including a small number of cytotoxic drugs. More recently …

The incidence of lung cancer in 2007 is estimated to be 213,380 with 160,390 deaths in the
United States. It contributed to 31% of male and 26% of female cancer-related deaths and is …

Pemetrexed is a novel multitargeting antimetabolite that has first-line and second-line
activity against nonsmall cell lung cancer (NSCLC). Phase II studies have shown significant …